RayKnowChina Research Map
Shortlist

Blood disorders

Lymphoma in Tianjin

天津 淋巴瘤

All diseases in Tianjin

4 hospitals in Tianjin

Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.

Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Tianjin may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.

  1. 56 papers led
  2. 34 papers led
  3. 21 papers led
    No open trial led
  4. 7 papers led

Lymphoma in every city Tianjin on the disease page, with the national map

90

open trials on lymphoma with a hospital in Tianjin

Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Tianjin as lead sponsor or study site. 42 of them are led by a hospital in Tianjin. Check the registry for the current status. Whether someone can take part is decided by the study team.

Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.

  1. Recruiting
    A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Phase
    Phase 4
    Started
    2026-03
    Posted
    Registry
    NCT07218341

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou

  2. Recruiting
    CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL
    Phase
    Phase 2
    Started
    2026-02
    Posted
    Registry
    NCT07397832

    Age 60 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  3. Recruiting
    A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
    Phase
    Phase 3
    Started
    2026-03
    Posted
    Registry
    NCT07409428

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou

  4. Recruiting
    Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
    Phase
    Phase 2
    Started
    2026-01
    Posted
    Registry
    NCT07441993

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 11 listed hospitals as study sitesBeijing, Changchun, Changsha, Guangzhou, Jinan, Nanchang, Nantong, Tianjin, Wuhan, Zhengzhou

  5. Recruiting
    Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07555470

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  6. Recruiting
    R-PMDT Regimen in Newly Diagnosed PCNSL
    Phase
    Phase 2
    Started
    2026-05
    Posted
    Registry
    NCT07604987

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  7. Recruiting
    A Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
    Phase
    Early phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07606937

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin

  8. Recruiting
    A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07609862

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  9. Recruiting
    Phase I Study of FXS0683 in the Treatment of Blood Tumors
    Phase
    Phase 1
    Started
    2026-06
    Posted
    Registry
    NCT07616089

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  10. Recruiting
    Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
    Phase
    Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06570447

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  11. Recruiting
    A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
    Phase
    Phase 3
    Started
    2025-01
    Posted
    Registry
    NCT06717347

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen

  12. Recruiting
    UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies
    Phase
    Phase 1
    Started
    2025-04
    Posted
    Registry
    NCT06743503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin

  13. Recruiting
    Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06829771

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou

  14. Recruiting
    Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06830031

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  15. Recruiting
    Newly-diagnosed Pediatric T-cell ALL Protocol
    Phase
    Phase 2/Phase 3
    Started
    2025-03
    Posted
    Registry
    NCT06855810

    Age 1 month to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan

  16. Recruiting
    A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies
    Phase
    Phase 1
    Started
    2025-03
    Posted
    Registry
    NCT06914037

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  17. Recruiting
    A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
    Phase
    Phase 3
    Started
    2025-06
    Posted
    Registry
    NCT06943872

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou

  18. Recruiting
    GT719 Injection for the Treatment of Recurrent/Refractory CD19 Positive Adult B-cell Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-04
    Posted
    Registry
    NCT06948981

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  19. Recruiting
    Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-05
    Posted
    Registry
    NCT06996132

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  20. Recruiting
    A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
    Phase
    Phase 2
    Started
    2025-08
    Posted
    Registry
    NCT07082686

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  21. Recruiting
    Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07106723

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  22. Recruiting
    CD180 CART for Relapsed or Refractory CD180 Positive Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07106749

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  23. Recruiting
    uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
    Phase
    Phase 1
    Started
    2025-06
    Posted
    Registry
    NCT07109518

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  24. Recruiting
    A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
    Phase
    Phase 3
    Started
    2025-09
    Posted
    Registry
    NCT07139873

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanjing, Tianjin

  25. Recruiting
    SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07153068

    Age 18 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  26. Recruiting
    Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07165769

    Age 18 years to 80 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  27. Recruiting
    PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
    Phase
    Phase 2
    Started
    2025-09
    Posted
    Registry
    NCT07188610

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou

  28. Recruiting
    A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07189065

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou

  29. Recruiting
    An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
    Phase
    Not given
    Started
    2025-09
    Posted
    Registry
    NCT07200375

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou

  30. Recruiting
    A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
    Phase
    Early phase 1
    Started
    2025-09
    Posted
    Registry
    NCT07205315

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  31. Recruiting
    Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-11
    Posted
    Registry
    NCT07259070

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  32. Recruiting
    Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07261163

    Age 18 years to 80 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  33. Recruiting
    A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 1
    Started
    2025-08
    Posted
    Registry
    NCT07283796

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  34. Recruiting
    Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
    Phase
    Phase 2
    Started
    2025-12
    Posted
    Registry
    NCT07299149

    Age 18 years to 90 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  35. Recruiting
    TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2024-03
    Posted
    Registry
    NCT06206174

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  36. Recruiting
    GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
    Phase
    Phase 2
    Started
    2024-01
    Posted
    Registry
    NCT06244368

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  37. Recruiting
    CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+
    Phase
    N/A
    Started
    2024-02
    Posted
    Registry
    NCT06355739

    Age 3 years to 18 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  38. Recruiting
    A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06363994

    Age 60 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  39. Recruiting
    ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
    Phase
    Phase 2/Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06378138

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi

  40. Recruiting
    Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06387121

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  41. Recruiting
    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2024-05
    Posted
    Registry
    NCT06395870

    Age 18 years to 75 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 1 listed hospital as study siteHefei, Tianjin

  42. Recruiting
    Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06445517

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Tianjin

  43. Recruiting
    CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06479356

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  44. Recruiting
    Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
    Phase
    Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06489808

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  45. Recruiting
    Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT06521255

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou

  46. Recruiting
    PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
    Phase
    Phase 2
    Started
    2024-08
    Posted
    Registry
    NCT06530550

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  47. Recruiting
    A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
    Phase
    Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06566586

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou

  48. Recruiting
    R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2024-05
    Posted
    Registry
    NCT06594640

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  49. Recruiting
    A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor
    Phase
    Phase 1
    Started
    2024-08
    Posted
    Registry
    NCT06615193

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 8 listed hospitals as study sitesHangzhou, Jinan, Nanchang, Suzhou, Tianjin, Xuzhou, Zhengzhou

  50. Recruiting
    Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06704555

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  51. Recruiting
    JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
    Phase
    Phase 2
    Started
    2024-12
    Posted
    Registry
    NCT06716658

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  52. Recruiting
    The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-11
    Posted
    Registry
    NCT06911710

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University General HospitalTianjin

  53. Recruiting
    A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
    Phase
    Phase 3
    Started
    2024-05
    Posted
    Registry
    NCT07234162

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou

  54. Recruiting
    A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2023-02
    Posted
    Registry
    NCT05800977

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou

  55. Recruiting
    Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
    Phase
    Phase 2
    Started
    2023-03
    Posted
    Registry
    NCT05958719

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  56. Recruiting
    Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
    Phase
    Phase 1
    Started
    2023-09
    Posted
    Registry
    NCT06047197

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  57. Recruiting
    A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
    Phase
    Phase 3
    Started
    2023-12
    Posted
    Registry
    NCT06136559

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Haikou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Taiyuan, Tianjin, Urumqi, Wuhan, Xuzhou, Zhengzhou

  58. Recruiting
    A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
    Phase
    Phase 1
    Started
    2022-03
    Posted
    Registry
    NCT05091424

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Nanchang, Tianjin

  59. Recruiting
    A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
    Phase
    Phase 3
    Started
    2022-07
    Posted
    Registry
    NCT05254743

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan

  60. Recruiting
    Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
    Phase
    Phase 2
    Started
    2022-04
    Posted
    Registry
    NCT05294055

    Age 18 years to 65 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 6 listed hospitals as study sitesBeijing, Hefei, Jinan, Tianjin, Zhengzhou

  61. Recruiting
    A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma
    Phase
    Phase 1
    Started
    2022-08
    Posted
    Registry
    NCT05341557

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesTianjin

  62. Recruiting
    Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia
    Phase
    Phase 2
    Started
    2022-08
    Posted
    Registry
    NCT05660473

    Age 14 years to 60 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  63. Recruiting
    Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2022-11
    Posted
    Registry
    NCT05846750

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  64. Recruiting
    Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study
    Phase
    Not given
    Started
    2022-11
    Posted
    Registry
    NCT05846763

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  65. Recruiting
    Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
    Phase
    Phase 2
    Started
    2021-04
    Posted
    Registry
    NCT04728893

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

  66. Recruiting
    A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT05006716

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou

  67. Recruiting
    Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Posted
    Registry
    NCT06021678

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesJinan, Tianjin, Zhengzhou

  68. Recruiting
    A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
    Phase
    Phase 1
    Started
    2021-03
    Posted
    Registry
    NCT06189391

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou

  69. Recruiting
    Evaluate the Safety and Clinical Activity of HH2853
    Phase
    Phase 1/Phase 2
    Started
    2020-09
    Posted
    Registry
    NCT04390737

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou

  70. Recruiting
    Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
    Phase
    Phase 1/Phase 2
    Started
    2020-08
    Posted
    Registry
    NCT04494503

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan

  71. Recruiting
    Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
    Phase
    Phase 2
    Started
    2020-10
    Posted
    Registry
    NCT04586478

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou

  72. Recruiting
    National Longitudinal Cohort of Hematological Diseases
    Phase
    Not given
    Started
    2020-12
    Posted
    Registry
    NCT04645199

    Age not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  73. Not yet recruiting
    Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
    Phase
    Phase 1
    Started
    2026-04
    Posted
    Registry
    NCT07539610

    Age 18 years to 69 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  74. Not yet recruiting
    A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
    Phase
    Phase 2
    Started
    2026-04
    Posted
    Registry
    NCT07585747

    Age 18 years to Not stated (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 4 listed hospitals as study sitesJinan, Nanchang, Shenzhen, Tianjin, Zhengzhou

  75. Not yet recruiting
    A Study of BEBT-908 in Combination With Chemotherapy in Patients With Previously Untreated Peripheral T-Cell Lymphoma (PTCL)
    Phase
    Phase 2
    Started
    2026-07
    Posted
    Registry
    NCT07676175

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesGuangzhou, Tianjin, Xi'an

  76. Not yet recruiting
    A Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07784101

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou

  77. Not yet recruiting
    SCTB35 and SCTB41 With or Without Chemotherapy in Non-Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2026-09
    Posted
    Registry
    NCT07819188

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteTianjin

  78. Not yet recruiting
    Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
    Phase
    Phase 3
    Started
    2026-10
    Posted
    Registry
    NCT07896590

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou

  79. Not yet recruiting
    Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure
    Phase
    Phase 2
    Started
    2026-12
    Posted
    Registry
    NCT07944651

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

  80. Not yet recruiting
    Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
    Phase
    Phase 1/Phase 2
    Started
    2025-02
    Posted
    Registry
    NCT06845241

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFuzhou, Guangzhou, Nanchang, Tianjin, Zhengzhou

  81. Not yet recruiting
    BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma
    Phase
    Phase 2
    Started
    2025-07
    Posted
    Registry
    NCT07008053

    Age 18 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 5 listed hospitals as study sitesChangsha, Fuzhou, Jinan, Qingdao, Shijiazhuang, Tianjin

  82. Not yet recruiting
    A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
    Phase
    Phase 2
    Started
    2025-06
    Posted
    Registry
    NCT07034508

    Age 18 years to 80 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  83. Not yet recruiting
    A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2025-07
    Posted
    Registry
    NCT07068906

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  84. Not yet recruiting
    Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
    Phase
    Phase 3
    Started
    2025-11
    Posted
    Registry
    NCT07187960

    Age 18 years to 80 years (registered criteria)

    Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou

  85. Not yet recruiting
    Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment
    Phase
    Phase 2
    Started
    2025-10
    Posted
    Registry
    NCT07206264

    Age 60 years to Not stated (registered criteria)

    Led by Tianjin Medical University Cancer Institute & Hospital; 3 listed hospitals as study sitesFuzhou, Harbin, Jinan, Tianjin

  86. Not yet recruiting
    A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
    Phase
    Phase 1
    Started
    2025-11
    Posted
    Registry
    NCT07234045

    Age 18 years to 75 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  87. Not yet recruiting
    A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma
    Phase
    Phase 1
    Started
    2024-04
    Posted
    Registry
    NCT06318884

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesBeijing, Tianjin, Zhengzhou

  88. Not yet recruiting
    Real World Study of Linperlisib for Lymphoma Treatment
    Phase
    Not given
    Started
    2023-05
    Posted
    Registry
    NCT05863871

    Age 18 years to Not stated (registered criteria)

    Led by Ruijin Hospital; 1 listed hospital as study siteShanghai, Tianjin

  89. Enrolling by invitation
    A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
    Phase
    Phase 1
    Started
    2026-08
    Posted
    Registry
    NCT07784309

    Age 3 years to 70 years (registered criteria)

    Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMCTianjin

  90. Enrolling by invitation
    AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH
    Phase
    Phase 3
    Started
    2023-01
    Posted
    Registry
    NCT05678933

    Age 18 years to 70 years (registered criteria)

    Led by Tianjin Medical University Cancer Institute & HospitalTianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

Disease research in Tianjin

Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.

A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.

Papers led and open trials led by hospitals in Tianjin, by disease
CancerBlood disordersOther diseases
HospitalNasopharyngeal carcinomaOesophageal squamous cell carcinomaHepatocellular carcinomaStomach cancerLung cancerPancreatic cancerBreast cancerGliomaHepatoblastomaRetinoblastomaChordomaOsteosarcomaGastrointestinal stromal tumourNeuroblastomaEwing sarcomaMultiple myelomaB-cell acute lymphoblastic leukaemiaAplastic anaemiaHaemophagocytic lymphohistiocytosisLymphomaBeta thalassaemiaHaemophilia AAtypical haemolytic uraemic syndromeThrombotic thrombocytopenic purpuraFanconi anaemiaNeuromyelitis optica spectrum disorderIgG4-related diseaseMyasthenia gravisMoyamoya diseaseWilson diseaseBiliary atresiaCoronary heart diseaseCongenital heart diseaseScoliosisAnti-NMDA receptor encephalitisTakayasu arteritisHepatic echinococcosisIdiopathic pulmonary fibrosisLymphangioleiomyomatosisAmyotrophic lateral sclerosisSpinal muscular atrophyFabry diseasePompe diseaseDuchenne muscular dystrophyBehçet diseaseAlport syndromeIgA nephropathyGaucher diseaseNiemann–Pick disease type COsteogenesis imperfectaPrimary biliary cholangitisPrimary sclerosing cholangitisCongenital diaphragmatic herniaHirschsprung diseaseInherited epidermolysis bullosaHereditary angioedemaFamilial adenomatous polyposisLeber hereditary optic neuropathyMajeed syndromeNGLY1 deficiencyISG15 deficiencyShortlist
Affiliated Hospital of Logistics University of Chinese People中国人民武装警察部队特色医学中心nonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone00none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Beichen District Tradicine Chinese Medicine Hospital天津市北辰区中医医院nonenonenonenonenonenonenonenonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Cangzhou Central Hospital沧州市中心医院2nonenone1130none2014none0none7121nonenonenonenonenonenone0nonenonenonenonenonenonenonenonenone6nonenonenone0nonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Affiliated Hospital of Nankai University天津市人民医院nonenonenonenonenonenonenonenonenonenonenone2none11nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
First Teaching Hospital, Tianjin University of Traditional Chinese Medicine天津中医药大学第一附属医院nonenonenonenone264 opennone54 opennonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenonenonenonenonenonenone6nonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
Haihe Hospital天津市海河医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)nonenonenonenonenonenonenonenonenonenonenonenonenone1none4728 open1312 open489 opennone3432 open1255 opennone03nonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenone1nonenonenone0nonenonenone1nonenonenonenonenonenonenonenonenone
Pingjin Hospital平津医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine天津中医药大学第二附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Second Hospital of Tianjin Medical University天津医科大学第二医院nonenonenone38nonenonenonenonenonenone01nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone234nonenonenonenone1nonenonenonenonenone1nonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenone
TEDA International Cardiovascular Hospital泰达国际心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone715nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
TEDA International Cardiovascular Hospital泰达国际心血管病医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone74nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Baodi Hospital天津市宝坻区人民医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Chest Hospital天津市胸科医院nonenonenonenone39nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone362 open4nonenonenonenone3nonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Children's Hospital天津市儿童医院nonenonenonenonenonenonenonenone2nonenonenonenone2nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone17nonenonenonenonenonenonenonenonenonenone0none2nonenone0nonenonenonenonenone12nonenonenonenonenonenonenone
Tianjin Eye Hospital天津市眼科医院nonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Fifth Central Hospital天津市第五中心医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin First Central Hospital天津市第一中心医院nonenone45none191 opennonenonenone1none1300none82nonenone21nonenonenone0nonenonenonenonenonenone933nonenone1none2none0nonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Tianjin Fourth Central Hospital天津市第四中心医院nonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Hospital天津市天津医院nonenonenonenonenonenonenonenonenonenonenone10none1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone7nonenonenone1nonenonenonenonenonenone0none1nonenone0nonenonenonenonenonenonenonenonenonenonenone
Tianjin Huanhu Hospital天津市环湖医院nonenonenonenonenonenonenone151 opennonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenone12 opennone02 opennonenonenonenonenonenone2nonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Jinnan Hospital天津市津南医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Medical University Baodi Hospital天津医科大学附属宝坻医院nonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院74712 open8811 open786 open25830 open7112 open24617 open141none1182211 open1101 opennonenonenone569 opennonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenone
Tianjin Medical University Eye Hospital天津医科大学眼科医院nonenonenonenonenonenonenonenonenone4nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Medical University General Hospital天津医科大学总医院1522301241020783 open11none320none271 open01 open23none71 opennonenonenone1none222 open3211 open2nonenone161nonenone0none7none11nonenone2none110nonenone471none0nonenone03nonenonenone
Tianjin Nankai Hospital天津市南开医院nonenonenonenonenone7nonenonenonenonenone0none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Port Hospital天津港口医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone
Tianjin Second People's Hospital天津市第二人民医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone3nonenonenonenonenonenonenonenonenonenone
Tianjin Third Central Hospital天津市第三中心医院nonenone30nonenonenonenonenonenonenonenone00none0nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone0nonenonenone0nonenonenonenonenonenonenonenonenonenone0nonenonenonenonenonenonenonenonenonenone
Traditional Chinese Medicine Affiliated Hospital天津市中医药研究院附属医院nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone1nonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenonenone

Column labels are short names. Choose one to open that disease in Tianjin.

Other cities nearby

Straight-line distance from the city centre; counts are hospitals listed for lymphoma.

Counts are listed hospitals only, not every hospital in each city.

Where these numbers come from

Papers

English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions

Trials

ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Tianjin on ClinicalTrials.gov

Locations

Locations are shown at city centres. Check the hospital’s website for its address.

Suggest a correctionDownload the data